Real-World Outcomes of Limited Resection for Tumours Greater Than 20 mm in Non-Small Cell Lung Cancer
Limited resection showed acceptable outcomes in lung cancers >20 mm, especially with ground-glass opacity; solid-predominant CT patterns were strongly linked to recurrence.
Authors
- Yasunori Sato (ORCID: https://orcid.org/0000-0001-8302-2069)
- Takao Shigenobu
- Kaoru Kaseda
- Ryutaro Hanawa
- Katsura Emoto (ORCID: https://orcid.org/0000-0002-4842-8116)
- Kyohei Masai
- Tomoyuki Hishida (ORCID: https://orcid.org/0000-0003-3417-8563)
- Keisuke Asakura (ORCID: https://orcid.org/0000-0002-4491-3456)
- Shigeki Suzuki (ORCID: https://orcid.org/0000-0002-8520-9393)
- Akio Kazama
Institutions
- Keio University (JP)
- National Sagamihara Hospital (JP)
- Saiseikai Utsunomiya hospital (JP)
Publication Details
- Journal
- European Journal of Cardio-Thoracic Surgery
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1093/ejcts/ezaf322
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Taiho Pharmaceutical
- Daiichi-Sankyo
- Astellas Pharma
- Shionogi
- Chugai Pharmaceutical
- Eli Lilly Japan
- Daiichi Sankyo Company